Skip to Content

EHA24: Severel Advances in the Treatment of Multiple Myeloma

In this MEDtalk, Fredrik Schjesvold, Oslo Myeloma Center, highlights several studies that have and will have great significance for treating multiple myeloma. He is also looking forward to EHA 2024, where he expects positive results from the IMROZ and the BENEFIT studies.

Fredrik Hellem Schjesvold

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top